CytomX Therapeutics’ (CTMX) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research report report published on Friday morning,Benzinga reports.

CytomX Therapeutics Trading Up 7.7 %

NASDAQ:CTMX opened at $0.66 on Friday. The firm has a market cap of $52.03 million, a P/E ratio of 3.91 and a beta of 1.05. The stock’s 50 day simple moving average is $0.84 and its 200-day simple moving average is $1.02. CytomX Therapeutics has a 12-month low of $0.60 and a 12-month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. The business had revenue of $38.09 million for the quarter, compared to analyst estimates of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. Research analysts forecast that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Miller Financial Services LLC acquired a new position in CytomX Therapeutics during the fourth quarter worth $26,000. Traphagen Investment Advisors LLC acquired a new position in CytomX Therapeutics during the fourth quarter worth $31,000. Algert Global LLC acquired a new position in CytomX Therapeutics during the fourth quarter worth $35,000. Velan Capital Investment Management LP acquired a new position in CytomX Therapeutics during the fourth quarter worth $36,000. Finally, US Bancorp DE acquired a new position in CytomX Therapeutics during the third quarter worth $40,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.